Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Plos One
|
June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
Jesús Troya, Rocio Montejano, Pablo Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 19, 2017
Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients
Rocio Montejano, Natalia Stella-Ascariz, Susana Monge, et al.
The Journal of Infectious Diseases
|
June 24, 2021
Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment
Andrés Esteban-Cantos, Rocio Montejano, Javier Rodríguez-Centeno, et al.
The Journal of Infectious Diseases
|
June 19, 2018
Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults
Rocio Montejano, Natalia Stella-Ascariz, Susana Monge, et al.
AIDS and Behavior
|
June 15, 2025
Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV
Joanna Cano-Smith, Ana Delgado-Hierro, Luis Ramos-Ruperto, et al.
The Journal of Antimicrobial Chemotherapy
|
August 30, 2021
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)
Rocio Montejano, Lourdes Dominguez-Dominguez, Rosa de Miguel, et al.
The New England Journal of Medicine
|
May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D Goldman, David C B Lye, David S Hui, et al.
The Lancet. HIV
|
June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial
Pablo Ryan, José L Blanco, Mar Masia, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Plos One
|
June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
Jesús Troya, Rocio Montejano, Pablo Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 19, 2017
Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients
Rocio Montejano, Natalia Stella-Ascariz, Susana Monge, et al.
The Journal of Infectious Diseases
|
June 24, 2021
Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment
Andrés Esteban-Cantos, Rocio Montejano, Javier Rodríguez-Centeno, et al.
The Journal of Infectious Diseases
|
June 19, 2018
Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults
Rocio Montejano, Natalia Stella-Ascariz, Susana Monge, et al.
AIDS and Behavior
|
June 15, 2025
Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV
Joanna Cano-Smith, Ana Delgado-Hierro, Luis Ramos-Ruperto, et al.
The Journal of Antimicrobial Chemotherapy
|
August 30, 2021
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)
Rocio Montejano, Lourdes Dominguez-Dominguez, Rosa de Miguel, et al.
The New England Journal of Medicine
|
May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D Goldman, David C B Lye, David S Hui, et al.
The Lancet. HIV
|
June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial
Pablo Ryan, José L Blanco, Mar Masia, et al.
Page
of 2